Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation Santos-Briz A, Romo A, Antúnez P, Román C, Alcoceba M, García JL, Vázquez L, González M, Unamuno P. Clinical and Experimental Dermatology 34(8):e778-81. FI: 1.550 (Q3) Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study de la Rubia J, Montesinos P, Martino R, Jarque I, Rovira M, Vázquez L, López J, Batlle M, de la Cámara R, Juliá A, Lahuerta JJ, Debén G, Díaz J, García R, Sanz MA. Biology of Blood and Marrow 15(4):512-6. FI: 3.149 (Q2) Hepatitis B reactivation in a hepatitis B surface antigen-negative patient after allogeneic bone marrow transplant: successful treatment with lamivudine and seroconversion Pérez-Grande R, Gutiérrez-Zufiaurre N, Muñoz-Criado S, Blázquez de Castro AM, Vázquez López L, González San Martín F, García Rodríguez JA, Muñoz Bellido JL. Diagnostic Microbiology and Infectious 64(1):80-2. FI: 2.451 (Q2) Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A, Baltadakis I, Dalle JH, Koc Y, Toporski J, Styczynski J, Yesilipek MA, Heinz W, Caniglia M, Rascón J, Fauser AA, Michallet M, López-Corral L, Neuburger S, Tridello G, Einsele H. Clinical Infectious Diseases 15:49(2): 233-40. FI: 8.180 (Q1) Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project Giraldo P, Alfonso P, Atutxa K, Fernández-Galán MA, Barez A, Franco R, Alonso D, Martín A, Latre P, Pocovi M. Haematologica 94(12):1771-5. FI: 6.416 (Q1) The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients Paiva B, Vidriales MB, Mateo G, Pérez JJ, Montalbán MA, Sureda A, Montejano L, Gutiérrez NC, García de Coca A, de Las Heras N, Mateos MV, López-Berges MC, García-Boyero R, Galende J, Hernández J, Palomera L, Carrera D, Martínez R, de la Rubia J, Martín A, González Y, Blade J, Lahuerta JJ, Orfao A, San Miguel JF. Blood 114(20):4369-72. FI: 10.555 (Q1) Immunomodulatory effect of mesenchymal stem cells Herrero C, Pérez-Simón JA. Brazilian Journal of Medical and Biological Research 43(5):425-30. FI: 1.075 (Q3) Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation Calvo-Villas JM, Martín A, Conde E, Pascual A, Heras I, Varela R, de la Rubia J, Ramírez MJ, Díez-Martín JL, Panizo C, Rodríguez-Salazar MJ, Pascual MJ, Donato EM, González-Barca E, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL/TAMO cooperative group). Annals of Oncology 21(9):1891-7. FI: 5.647 (Q1) Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer MJ, Chiappella A, Briones J, Petrini M, Barbato A, Kayitalire L, Federico M. Annals of Oncology 21(7):1492-9. FI: 5.647 (Q1) Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials Piñana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL, Vázquez L, Arranz R, Tomás JF, Sampol A, Solano C, Delgado J, Sierra J, Caballero D, for the GELTAMO Group. Haematologica 95(7):1176-82. FI: 6.416 (Q1)
|
